Pharvaris NV

Viviane Monges, a Director of Pharvaris N.V., sold 11,969 shares of common stock on September 23, 2026 for $33.05 per share.

Peng Lu, President of Pharvaris N.V., reported multiple transactions in common stock on September 22, 2026.

Johannes Gerardus Christiaan Petrus Schikan, a Director of Pharvaris N.V., sold 800 shares of common stock on September 22, 2026 for $36.19 per share.

David W. Nassif, CFO / CLO of Pharvaris N.V., sold 6,000 shares of common stock on September 21, 2026 for $36.47 per share.

Peng Lu, President of Pharvaris N.V., sold 100,000 shares of common stock on September 17, 2026 for $35.00 per share.

Johannes Gerardus Christiaan Petrus Schikan, a Director of Pharvaris N.V., sold 200,000 shares of common stock on September 17, 2026 for $35.00 per share.

General Atlantic entities have collectively adjusted their beneficial ownership of Pharvaris N.V. ordinary shares to 7.6%, as reported in an amended Schedule 13G filing.

LSP V Cooperatieve U.A. and LSP V Management B.V. report a 4.9% stake in Pharvaris N.V. as of June 30, 2026.

Viking Global Investors LP filed an amendment to its Schedule 13G, reporting a 5.6% beneficial ownership stake in Pharvaris N.V. following the retirement of David C. Ott.

Bain Capital Life Sciences entities have disclosed a collective beneficial ownership of 5.1% in Pharvaris N.V., totaling 3,181,275 ordinary shares as of September 30, 2025.

A group of investors led by Venrock Healthcare Capital Partners has reduced its beneficial ownership in Pharvaris N.V. to 3.8% of ordinary shares.